Finnish clinical stage biopharmaceutical company, Faron Pharmaceuticals, has raised five million pounds (approx. 5.8 million euros) in funding, which will go towards the development of its immuno-oncology drug, Clevegen.
The post Faron Pharmaceuticals raises GBP 5 million appeared first on Good News from Finland.